Illumina (ILMN) Q2 EPS Jumps 9%

Illumina (NASDAQ:ILMN), a global leader in DNA sequencing and genomics, released its second quarter results on July 31, 2025, for the fiscal 2025 period. The results were notable for beating analyst expectations on both non-GAAP EPS and GAAP revenue. Non-GAAP earnings per share reached $1.19, compared to the $1.01 non-GAAP consensus. Revenue (GAAP) landed at $1.06 billion, just ahead of the $1.05 billion estimate—though down 3% from the prior year. Management also provided a modestly improved full-year outlook, raising non-GAAP operating margin guidance to approximately 22%–22.5% (from 21.5%–22.0% previously) and non-GAAP diluted EPS guidance to $4.45–$4.55 (from $4.20–$4.30 previously), highlighting better-than-expected performance in clinical markets and strong adoption of its latest X consumables. The quarter showed strong margin improvement, with non-GAAP operating margin of 20.4%, but revenue growth remains under pressure due to weak research demand and a shrinking contribution from China. Overall, earnings reflected cost discipline, with buybacks and tax benefits lifting per-share numbers. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Illumina sells DNA sequencing equipment, software, and associated supplies to customers worldwide. Its primary users span clinical laboratories, research centers, and healthcare providers who rely on genomic analysis for disease research, diagnosis, and treatment planning. Its portfolio features high-throughput sequencers, including the NovaSeq X platform, as well as lower-throughput options like the MiSeq i100, alongside consumables, software, and informatics solutions.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool